Fellow in Cardiology, Duke University, Medicine
As of 2008 · Last known relationship
James Steven Mills is a Duke cardiology faculty member whose work spans interventional cardiology, cardiovascular outcomes, and translational device research. He is listed as an Assistant Professor of Medicine at Duke University. His earlier training included residency at Children’s Hospital, Boston (2000–2003), followed by a Duke cardiology fellowship (2003–2008), after earning an M.D. from the University of Florida in 2000. His publications address infarct-size prediction and biomarker analysis after myocardial infarction, peripheral arterial disease in heart failure, endovascular treatment of femoral artery occlusions, and optical or cell-based approaches to coronary stents. His documented awards include NIH-supported PTEN gene therapy research in vein graft disease (2009–2012) and a Procyrion-supported observational study of cardiorenal syndrome (2019–2021).
Each topic is linked to its supporting source in Sources.
Training includes Fellow in Cardiology, Duke University, Medicine, Resident, Children's Hospital, Boston, Medicine, M.D., University of Florida, and Assistant Professor of Medicine, plus 1 more record.
Explore education and training2021
2012
As of 2008
As of 2003
As of 2000
Effect of peripheral arterial disease on functional and clinical outcomes in patients with heart failure (from HF-ACTION).[6]
ENDOVASCULAR RECANALIZATION OF SUPERFICIAL FEMORAL ARTERY CHRONIC TOTAL OCCLUSIONS: A MULTI-DISCIPLINARY, SINGLE CENTER EXPERIENCE.[6]
High risk percutaneous coronary intervention and intra-aortic balloon pumps: when is the safety net needed?[6]
Importance of total ischemic time and preprocedural infarct-related artery blood flow in predicting infarct size in patients with anterior wall myocardial infarction (from the CRISP-AMI Trial).[6]
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy.[6]
OPTICAL COHERENCE TOMOGRAPHY ACCURATELY DETERMINES NEOINTIMAL COVERAGE AND STENT AREA OF BARE METAL AND DRUG-ELUTING CORONARY STENTS.[6]
Point-of-Care Seeded Blood-Derived Endothelial Cells Rapidly Endothelialize Nitinol Stent in a Pig Model of Personalized Cell Therapy.[6]
Point-of-care seeding of nitinol stents with blood-derived endothelial cells.[6]
Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction.[6]
The impact of processes of care on myocardial infarct size in patients with ST-segment elevation myocardial infarction: observations from the CRISP-AMI trial.[6]